Not sure if this has been posted before, if so, apologies in advance. The bold is mine.

Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents

https://elifesciences.org/articles/103245

https://doi.org/10.7554/eLife.103245.3.sa0

Quote:

---

eLife Assessment:
This study is important, and the findings add substantially to the evidence base regarding CCR5 antagonist drugs for neuroprotection and stroke management. The authors adhered to the expected systematic review and meta-analysis standards, and the presented evidence is convincing .

---

Quote:

---

In conclusion, CCR5 antagonists show promise in preclinical studies for stroke cerebroprotection, corresponding reduction in impairment, as well as improved functional recovery related to neural repair in the late subacute/early chronic phase. However, high risk of bias and the limited (or no) evidence in clinically relevant domains underscore the need for more rigorous and transparent preclinical research to further strengthen the current preliminary evidence available in the literature.

---